Core Insights - Hapbee Technologies Inc. is advancing research on three new frequency wellness signals: Hunger Management, Allergy Comfort, and Sexual Vitality, aiming to broaden its platform's usage and reinforce its leadership in frequency wellness [1][10] - The new signals are designed to help users support balance, comfort, and confidence in their daily lives, emphasizing a natural approach to wellness without medical claims [2][5] Product Development - The three new signals are currently in the research and development phase and are not intended for medical or therapeutic use, with pilot experiences expected to begin later this year [7] - Hapbee's existing signal library includes Sleep, Focus, Calm, Energy, and Strain Relief, which has powered millions of wellness sessions globally [8] Company Mission and Philosophy - The company aims to provide a safe and natural way for individuals to enhance their wellbeing without the use of pharmaceuticals, focusing on energy and technology to restore balance [5][9] - Hapbee's technology engages the body's natural energetic systems, promoting harmony and wellbeing through frequency patterns rather than chemical ingestion [3][4] Financial Update - Hapbee has closed a non-brokered private placement, issuing 7,425,000 units at a price of CAD$0.10 per unit, resulting in gross proceeds of CAD$742,500 [9][11] - The net proceeds from this offering will be allocated to product and business development, as well as general corporate purposes [13] Leadership Changes - The company has appointed Krishna Subramanian as a new board member and Chief Financial Officer, indicating a strategic move to strengthen its leadership team [14]

Core Insights - Psyched Wellness Ltd. is advancing its product offerings, particularly focusing on the dietary supplement shot named Santa, with a soft launch scheduled for October 1, 2025 [2] - The company is conducting scientific studies to ensure the safety and efficacy of its proprietary extract, AME-1, derived from the Amanita Muscaria mushroom [3][4] - Regulatory compliance is a priority, with the company having submitted a New Dietary Ingredient Notification to the FDA for AME-1, despite receiving feedback regarding safety expectations [6] Product Development & Launches - The initial production run of the dietary supplement shot, Santa, was completed on September 15, 2025, in preparation for a soft launch on October 1, 2025 [2] - A second production run is planned for mid-October to ensure sufficient inventory for the holiday season [2] Scientific Studies - A Genotoxicity Study on AME-1 was initiated on March 14, 2025, with promising progress reported [3] - A six-month accelerated stability study confirmed that AME-1 maintains its muscimol content for up to 18 months, extending its shelf life from 12 months to 18 months [4] Patents - The company submitted a "scaled-up extraction process" patent application to the USPTO on August 18, 2025, which is currently pending in the U.S. and Canada [5] Regulatory Update - In July 2025, the company submitted a New Dietary Ingredient Notification (NDIN) to the FDA for AME-1, including over 100 years of documented food use of Amanita muscaria [6] - The FDA's response indicated that the data did not demonstrate that AME-1 "will reasonably be expected to be safe," but the company maintains confidence in the safety of AME-1 based on historical use and its own safety studies [6]